Bergman AM - Search Results

1

Concurrent Radiotherapy and Panitumumab after Lymph Node Dissection and Induction Chemotherapy for Invasive Bladder Cancer.

Fransen van de Putte EE, Pos F, Doodeman B, van Rhijn BWG, van der Laan E, Nederlof P, van der Heijden MS, Bloos-van der Hulst J, Sanders J, Broeks A, Kerst JM, van der Noort V, Horenblas S, Bergman AM. Fransen van de Putte EE, et al. Among authors: bergman am. J Urol. 2019 Mar;201(3):478-485. doi: 10.1016/j.juro.2018.10.007. J Urol. 2019. PMID: 30321552

2

18F-FDG PET/CT for monitoring induction chemotherapy in patients with primary inoperable penile carcinoma: first clinical results.

Graafland NM, Valdés Olmos RA, Teertstra HJ, Kerst JM, Bergman AM, Horenblas S. Graafland NM, et al. Among authors: bergman am. Eur J Nucl Med Mol Imaging. 2010 Aug;37(8):1474-80. doi: 10.1007/s00259-010-1434-0. Epub 2010 Mar 27. Eur J Nucl Med Mol Imaging. 2010. PMID: 20349185

3

Carboplatin based induction chemotherapy for nonorgan confined bladder cancer--a reasonable alternative for cisplatin unfit patients?

Mertens LS, Meijer RP, Kerst JM, Bergman AM, van Tinteren H, van Rhijn BW, Horenblas S. Mertens LS, et al. Among authors: bergman am. J Urol. 2012 Oct;188(4):1108-13. doi: 10.1016/j.juro.2012.06.018. Epub 2012 Aug 15. J Urol. 2012. PMID: 22901581

4

Response to induction chemotherapy and surgery in non-organ confined bladder cancer: a single institution experience.

Meijer RP, Nieuwenhuijzen JA, Meinhardt W, Bex A, van der Poel HG, van Rhijn BW, Kerst JM, Bergman AM, van Werkhoven E, Horenblas S. Meijer RP, et al. Among authors: bergman am. Eur J Surg Oncol. 2013 Apr;39(4):365-71. doi: 10.1016/j.ejso.2013.01.003. Epub 2013 Jan 31. Eur J Surg Oncol. 2013. PMID: 23375648

5

Occult lymph node metastases in patients with carcinoma invading bladder muscle: incidence after neoadjuvant chemotherapy and cystectomy vs after cystectomy alone.

Mertens LS, Meijer RP, Meinhardt W, van der Poel HG, Bex A, Kerst JM, van der Heijden MS, Bergman AM, Horenblas S, van Rhijn BW. Mertens LS, et al. Among authors: bergman am. BJU Int. 2014 Jul;114(1):67-74. doi: 10.1111/bju.12447. Epub 2014 Jan 17. BJU Int. 2014. PMID: 24053889

6

Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatment.

Badrising S, van der Noort V, van Oort IM, van den Berg HP, Los M, Hamberg P, Coenen JL, van den Eertwegh AJ, de Jong IJ, Kerver ED, van Tinteren H, Bergman AM. Badrising S, et al. Among authors: bergman am. Cancer. 2014 Apr 1;120(7):968-75. doi: 10.1002/cncr.28518. Epub 2013 Dec 30. Cancer. 2014. PMID: 24382803 Free article.

7

Neoadjuvant taxane-based combination chemotherapy in patients with advanced penile cancer.

Djajadiningrat RS, Bergman AM, van Werkhoven E, Vegt E, Horenblas S. Djajadiningrat RS, et al. Among authors: bergman am. Clin Genitourin Cancer. 2015 Feb;13(1):44-9. doi: 10.1016/j.clgc.2014.06.005. Epub 2014 Jun 8. Clin Genitourin Cancer. 2015. PMID: 25009098

8

Neoadjuvant induction dose-dense MVAC for muscle invasive bladder cancer: efficacy and safety compared with classic MVAC and gemcitabine/cisplatin.

van de Putte EE, Mertens LS, Meijer RP, van der Heijden MS, Bex A, van der Poel HG, Kerst JM, Bergman AM, Horenblas S, van Rhijn BW. van de Putte EE, et al. Among authors: bergman am. World J Urol. 2016 Feb;34(2):157-62. doi: 10.1007/s00345-015-1636-y. Epub 2015 Jul 17. World J Urol. 2016. PMID: 26184106

9

Prognostic parameters for response to enzalutamide after docetaxel and abiraterone treatment in metastatic castration-resistant prostate cancer patients; a possible time relation.

Badrising SK, van der Noort V, van den Eertwegh AJ, Hamberg P, van Oort IM, van den Berg HP, Los M, Aarts MJ, Coenen JL, Gelderblom H, de Jong IJ, Kerver ED, Vrijaldenhoven S, van Voorthuizen T, Warmerdam F, Haanen JB, Bergman AM; Dutch Uro-Oncology Studygroup. Badrising SK, et al. Among authors: bergman am. Prostate. 2016 Jan;76(1):32-40. doi: 10.1002/pros.23094. Epub 2015 Sep 22. Prostate. 2016. PMID: 26390914

10

mTOR pathway activation is a favorable prognostic factor in human prostate adenocarcinoma.

Stelloo S, Sanders J, Nevedomskaya E, de Jong J, Peters D, van Leenders GJ, Jenster G, Bergman AM, Zwart W. Stelloo S, et al. Among authors: bergman am. Oncotarget. 2016 May 31;7(22):32916-24. doi: 10.18632/oncotarget.8767. Oncotarget. 2016. PMID: 27096957 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

168 results

Search Page